| Quantity | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 5 mg, 10 mg, 25 mg, 50 mg | 500 µ, g, 1 mg, 5 mg, 10 mg | 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | 5 mg, 10 mg |
| Description | CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects[1][2][3]... Read More | Enfuvirtide (T20; DP178) acetate is an anti-HIV-1 fusion inhibitor peptide | GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells[1] | Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis[1][2] | TCTDSTNCYKAT is an engineered-variant peptide of antifreeze protein (AFP)[1] |